Sofinnova Bets On Italy With New Biotech Accelerator
This article was originally published in Scrip
Executive Summary
Italy's biotech sector may have lagged that of other developed countries but change may be afoot as European venture capital firm Sofinnova Partners has launched the country's first biotech accelerator.
You may also be interested in...
Finance Watch: The Rush To End 2023 With Fresh VC Cash For Biopharma
Private Company Edition: Playground’s third fund has $410m for tech, including biotech, Pivotal Life Sciences closed its second fund with $389m and Chugai will invest $200m through its new fund. Also, Tome launched with $213m, Sudo raised a $116m series B and Odyssey closed a $101m in series C.
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.